The Abramson Cancer Center of the University of Pennsylvania?
Last Modified: January 6, 2011
Dates: April 8, 2011, 8am - 3pm
Location: Hilton Hotel, 4200 City Avenue, Philadelphia, PA
Topics Covered: The incidence of head and neck cancers and the impact of this disease on men and women, of all ages, have made head and neck cancers a priority for Penn's Abramson Cancer Center.
Agenda: For those diagnosed with a head and neck cancer it is just the beginning of a long, challenging journey. Together with their family, patients' face a myriad of issues surrounding initial diagnosis, deciding the treatment modality that is best for them, on-going treatment and symptom management decisions, and the possibility of recurrence. The care requirements and the high level of accompanying emotional distress create the critical need for easily accessible, substantial patient education. Through a series of presentations, panels, workshops and the opportunity to network and gain support from other survivors, the conference will serve to educate patients and their families about the medical and psychosocial issues they may face. An educational conference highlighting the latest advances in diagnosis, treatment, symptom management and psychosocial issues will provide patient-focused information that will enhance the patient's peace of mind and sense of well-being. The conference is designed for people who are survivors of head and neck cancers, their families, friends and caregivers whose lives have been affected by cancer.
Registration Information: Online and Phone Registration will open as the event nears. For more information, email Barbara Lopez at firstname.lastname@example.org
Sep 19, 2014 - The investigational drug alpelisib (previously known as BYL719) appears to inhibit activation of the pathway that leads to resistance to cetuximab, an anti-epidermal growth factor receptor agent used in the treatment of head and neck cancer. These findings were presented at the American Association for Cancer Research's special conference "Targeting the PI3K-mTOR Network in Cancer," held from Sept. 14 to 17 in Philadelphia.